Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjogren's Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Nov 2021 Results assessing possible options for alternative responder definitions that indicate the optimal balance of sensitivity and specificity from dour trials ((NCT02962895, NCT02775916; NCT02291029; NCT02149420) presented at the ACR Convergence 2021
15 Jun 2019 Results (n=25) testing IV versus SC loading doses of iscalimab followed by SC maintenance dosing, presented at the 20th Annual Congress of the European League Against Rheumatism.
14 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com